CH stock · Healthcare sector · Biotechnology
Company Logo

CRISPR Therapeutics AG

CRSPNASDAQ

63.79

USD
+3.02
(+4.97%)
Market Closed
16.19P/E
-8Forward P/E
0.84P/E to S&P500
4.941BMarket CAP
- -Div Yield
Upcoming Earnings
9 May
Shares Short
6/15/22
10.64M
Short % of Float
15.91%
Short % of Shares Outs.
13.73%
% Held by Insiders
1.34%
% Held by Institutions
61.49%
Beta
2.03
PEG Ratio
0.04
52w. high/low
155.87/42.51
Avg. Daily Volume
1.75M
Return %
Stock
S&P 500
1 year
(58.82)
(11.88)
3 years
34.86
28.07
5 years
302.21
57.17
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
23.97
13.75
25.00
11.63
73.90
22.22
74.00
27.15
181.42
32.30
220.20
67.15
79.40
42.51
Currency: USD
- -
- -
- -
- -
- -
- -
- -
- -
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.42
1.02
0.07
5.32
0.01
13.87
11.96
Earnings per share
- -
- -
- -
- -
- -
- -
- -
- -
(0.23)
(1.28)
(1.89)
(1.71)
(3.44)
1.23
(5.29)
5.73
4.18
FCF per share
- -
- -
- -
- -
- -
- -
- -
- -
(0.16)
2.88
(4.76)
(1.94)
(2.06)
0.92
(3.89)
6.93
5.42
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.06
0.25
0.20
0.06
0.12
0.28
1.24
1.18
Book Value per sh.
- -
- -
- -
- -
- -
- -
- -
- -
(0.24)
(1.44)
19.00
4.69
8.18
17.27
25.23
36.38
31.91
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
- -
- -
29
20
12
40
48
54
66
66
76
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(9.9)
(10.9)
(13.6)
36.6
(15.0)
21.6
16.2
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.4)
(0.5)
(0.5)
1.5
(0.4)
0.7
0.8
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
0
5
41
3
290
1
915
915
Operating margin
- -
- -
- -
- -
- -
- -
- -
- -
(Infinity)%
(10,416.6)%
(1,319.3)%
(157.7)%
(5,087.8)%
16.1%
(49,295.5)%
40.8%
(28,885.6)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
- -
- -
0
0
1
3
4
5
9
18
21
Net profit (m)
- -
- -
- -
- -
- -
- -
- -
- -
(7)
(26)
(23)
(68)
(165)
67
(349)
378
312
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
0.9%
(0.0)%
(2.1)%
(2.6)%
(0.3)%
0.7%
(0.2)%
0.5%
0.1%
Net profit margin
- -
- -
- -
- -
- -
- -
- -
- -
(Infinity)%
(10,456.7)%
(449.3)%
(166.7)%
(5,281.1)%
23.1%
(48,520.9)%
41.3%
(29,281.4)%
Working capital (m)
- -
- -
- -
- -
- -
- -
- -
- -
(1)
147
298
234
439
930
1,622
2,298
2,147
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
38
- -
- -
- -
- -
50
213
228
Equity (m)
- -
- -
- -
- -
- -
- -
- -
- -
(7)
(29)
233
188
392
939
1,664
2,399
2,245
ROIC
- -
- -
- -
- -
- -
- -
- -
- -
892.4%
(17.2)%
(4.6)%
(26.6)%
(35.8)%
6.6%
(20.1)%
14.3%
12.7%
Return on capital
- -
- -
- -
- -
- -
- -
- -
- -
(495.9)%
(16.1)%
(4.3)%
(24.5)%
(33.6)%
6.3%
(19.0)%
13.8%
12.1%
Return on equity
- -
- -
- -
- -
- -
- -
- -
- -
95.5%
88.8%
(10.0)%
(36.4)%
(42.1)%
7.1%
(21.0)%
15.7%
13.9%
Plowback ratio
- -
- -
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(830.2)%
- -
(46.6)%
0.3%
Capital Structure
9 May · 2022 | Q1
All numbers in millions
Total liabilities
$ 361
Total assets
$ 2,606
Long-term debt
$ 228
Cash and equiv.
$ 684
Goodwill
$ - -
Retained earnings
$ (375)
Common stock
77
Enterprise Value
$ 4,485
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
944
1,690
2,379
Receivables
0
0
0
Inventory
- -
- -
- -
Other
44
251
17
Current assets
988
1,717
2,418
Acc. Payable
6
9
15
Debt due
8
11
12
Other
43
74
93
Current liabilities
57
94
120
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
127,154.94%
34,033.16%
- -
Cash flow
(278.12)%
(253.76)%
- -
Earnings
(208.25)%
(207.31)%
- -
Dividends
- -
- -
- -
Book value
44.18%
92.42%
- -
Insider Trading
Type
Shares
Date
Kulkarni Samarth
Exempt
25,000
06/29/22
Kulkarni Samarth
Sale
4,740
06/29/22
Kulkarni Samarth
Sale
20,260
06/29/22
Kulkarni Samarth
Exempt
25,000
06/29/22
Behbahani Ali
Award
12,000
06/09/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
0
0
0
0
1
2021
1
901
1
13
915
2022
0
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(1.06)
(1.21)
(1.40)
(1.62)
(5.29)
2021
(1.72)
11.51
(1.93)
(2.14)
5.73
2022
(2.32)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Dr. Samarth Kulkarni
Full-time employees:
473
City:
Zug
Address:
Baarerstrasse 14
IPO:
Oct 19, 2016
Website:
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Recent News